[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100132271":3},{"organization":4,"armGroups":7,"interventions":34,"overallOfficials":78,"centralContacts":11,"locations":82,"responsibleParty":96,"collaborators":11,"id":98,"slug":99,"hasResults":100,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":11,"eligibilityCriteria":104,"healthyVolunteers":105,"sex":106,"minAge":107,"maxAge":108,"enrollmentInfo":109,"targetDuration":11,"studyType":112,"phases":113,"briefSummary":115,"conditions":116,"keywords":118,"overallStatus":120,"whyStopped":11,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":130},{"fullName":5,"class":6},"Sequella, Inc.","INDUSTRY",[8,15,18,21,24,27,30],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort 1","EXPERIMENTAL",null,[13,14],"Drug: PNU-100480","Drug: Placebo",{"label":16,"type":10,"description":11,"interventionNames":17},"Cohort 2",[13,14],{"label":19,"type":10,"description":11,"interventionNames":20},"Cohort 3",[13,14],{"label":22,"type":10,"description":11,"interventionNames":23},"Cohort 4",[13,14],{"label":25,"type":10,"description":11,"interventionNames":26},"Cohort 5",[13,14],{"label":28,"type":10,"description":11,"interventionNames":29},"Cohort 6 (optional)",[13,14],{"label":31,"type":10,"description":11,"interventionNames":32},"Linezolid Cohort",[33],"Drug: Linezolid",[35,40,44,47,50,53,56,59,62,65,68,71,74],{"type":36,"name":37,"description":38,"armGroupLabels":39,"otherNames":11},"DRUG","PNU-100480","100 mg BID for 14 days",[9],{"type":36,"name":41,"description":42,"armGroupLabels":43,"otherNames":11},"Placebo","to match 100 mg BID for 14 days",[9],{"type":36,"name":37,"description":45,"armGroupLabels":46,"otherNames":11},"300 mg BID for 14 days",[16],{"type":36,"name":41,"description":48,"armGroupLabels":49,"otherNames":11},"to match 300 mg BID for 14 days",[16],{"type":36,"name":37,"description":51,"armGroupLabels":52,"otherNames":11},"600 mg BID for 14 days",[19],{"type":36,"name":41,"description":54,"armGroupLabels":55,"otherNames":11},"to match 600 mg BID for 14 days",[19],{"type":36,"name":37,"description":57,"armGroupLabels":58,"otherNames":11},"1200 mg QD for 14 days",[22],{"type":36,"name":41,"description":60,"armGroupLabels":61,"otherNames":11},"to match 1200 mg QD for 14 days",[22],{"type":36,"name":37,"description":63,"armGroupLabels":64,"otherNames":11},"600 mg BID for 28 days with pyrazinamide (25 mg\u002Fkg up to 2 g) QD on Days 27-28",[25],{"type":36,"name":41,"description":66,"armGroupLabels":67,"otherNames":11},"placebo to match 600 mg BID for 28 days with pyrazinamide (25 mg\u002Fkg up to 2 g) QD on Days 27-28",[25],{"type":36,"name":37,"description":69,"armGroupLabels":70,"otherNames":11},"PNU-100480 dose up to total of 1200 mg daily for 28 days with pyrazinamide (25 mg\u002Fkg up to 2 g) QD on Days 27-28",[28],{"type":36,"name":41,"description":72,"armGroupLabels":73,"otherNames":11},"placebo to match dose up to total of 1200 mg daily for 28 days with pyrazinamide (25 mg\u002Fkg up to 2 g) QD on Days 27-28",[28],{"type":36,"name":75,"description":76,"armGroupLabels":77,"otherNames":11},"Linezolid","300 mg QD for 4 days (open label)",[31],[79],{"name":80,"affiliation":5,"role":81},"Lisa Beth Ferstenberg, M.D.","STUDY_DIRECTOR",[83],{"facility":84,"status":11,"city":85,"state":86,"zip":87,"country":88,"countryCode":89,"cosmosGeoPoint":90,"geoPoint":95,"contacts":11},"Pfizer Investigational Site","New Haven","Connecticut","06511","United States","US",{"type":91,"coordinates":92},"Point",[93,94],-72.92816,41.30815,{"lat":94,"lon":93},{"type":97,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100132271","phase-1-safety-tolerability-pharmacokinetics-and-measurement-of-whole-blood-activity-wba-of-pnu-100480-after-multiple-oral-doses-in-healthy-adult-volunteers-100132271",false,"NCT00990990","Safety, Tolerability, Pharmacokinetics And Measurement Of Whole Blood Activity (WBA) Of PNU-100480 After Multiple Oral Doses In Healthy Adult Volunteers","A Phase 1, Double-Blind, Randomized, Placebo-Controlled Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PNU-100480 (PF-02341272) After Administration Of Multiple Escalating Oral Doses To Healthy Adult Subjects","Inclusion Criteria:\n\n* Healthy adult volunteers willing and able to be confined to the Clinical Research Unit and comply with study schedule.\n* Women of non-childbearing potential only.\n\nExclusion Criteria:\n\n* History of hypersensitivity to, or intolerance of, linezolid.\n* Antibiotic treatment within 14 days prior to dosing, or any previous antibiotic use at the discretion of the investigator.\n* Previous history of irritable bowel syndrome (IBS) or inflammatory bowel disease (IBD).",true,"ALL","18 Years","55 Years",{"count":110,"type":111},59,"ACTUAL","INTERVENTIONAL",[114],"PHASE1","The purpose of this study is to assess the safety, tolerability and pharmacokinetics of multiple doses of PNU-100480 given for 14 or 28 days. Killing activity against the bacterium that causes tuberculosis (TB) will also be measured. The effect of adding an additional tuberculosis (TB) agent (given for 2 days) in addition to PNU-100480 will be evaluated. Linezolid open label to determine activity in whole blood assay (WBA).",[117],"Tuberculosis",[119],"Safety tolerability pharmacokinetics (PK) pharmacodynamics whole blood activity (WBA) PNU-100480 linezolid pyrazinamide multiple dose","COMPLETED","2013-08-27",{"date":123,"type":124},"2013-08-28","ESTIMATED",{"date":126,"type":11},"2009-10",{"date":128,"type":111},"2010-05",{"name":5,"class":6},1]